Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 18/20 | 1.00 |
| ▸ | GRM5 | P41594 | 13/20 | 0.78 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1837387 | 1.00 | GRM1 (1.00) | GRM1GRM5RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1837391 | 1.00 | GRM1 (1.00) | GRM1GRM5RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1837379 | 0.89 | GRM1 (1.00) | GRM1GRM5 | |
| SCHEMBL1837375 | 0.89 | GRM1 (1.00) | GRM1GRM5 | |
| SCHEMBL1837378 | 0.89 | GRM1 (1.00) | GRM1GRM5 | |
| SCHEMBL1841820 | 0.88 | GRM1 (1.00) | GRM1GRM5 | |
| SCHEMBL1841816 | 0.88 | GRM1 (1.00) | GRM1GRM5 | |
| SCHEMBL1840420 | 0.88 | GRM1 (1.00) | GRM1GRM5 | |
| SCHEMBL1841818 | 0.88 | GRM1 (1.00) | GRM1GRM5 | |
| SCHEMBL1840423 | 0.88 | GRM1 (1.00) | GRM1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960419-B2 | Substituted carboxamides | ELI LILLY AND COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2076502-B1 | SUBSTITUTED CARBOXAMIDES AS GROUP I METABOTROPIC RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20090182025-A1 | SUBSTITUTED CARBOXAMIDES | ELI LILLY AND COMPANY | 2009-07-16 | — | — | US | disclosed |
| EP-2076502-A2 | SUBSTITUTED CARBOXAMIDES AS GROUP I METABOTROPIC RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008103185-A2 | SUBSTITUTED CARBOXAMIDES AS GROUP I METABOTROPIC RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182025-A1 | SUBSTITUTED CARBOXAMIDES | CNR2, TRPV1, CNR1 | GRM1 675/4885GRM5 507/4885RAB9A 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.